THURSDAY, Aug. 15, 2024 -- The U.S. Food and Drug Administration has approved Nemluvio (nemolizumab) for adult patients living with prurigo...

The FDA approves Ascendis' (ASND) Yorvipath (palopegteriparatide) as the first and only treatment for hypoparathyroidism in adult patients. Shares...

Bumblefoot, scientifically known as pododermatitis, is a common, painful yet serious bacterial infection that affects the feet of chickens. This...

NEW YORK – The global eradication of smallpox more than 40 years ago was one of the greatest achievements in public health history, vanquishing a...

Gilead (GILD) wins FDA nod for seladelpar for the treatment of primary biliary cholangitis (PBC) on an accelerated basis.

Zug, Switzerland – August 13, 2024 – Galderma today announced that the U.S. Food and Drug Administration (FDA) has approved Nemluvio...

COPENHAGEN, Denmark, Aug. 12, 2024 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that the U.S. Food & Drug Administration...

RARITAN, N.J., Aug. 20, 2024 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) announced today that the U.S. Food and Drug Administration (FDA)...

CRANFORD, N.J., Aug. 8, 2024 /PRNewswire/ -- Citius Pharmaceuticals, Inc. (NASDAQ: CTXR) ("Citius", "Citius Pharma"), announced today that the U.S....